TRACERx 100: RNAseq data from the first 100 TRACERx tumours
TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). This study looks at the multi-region RNAseq data from the TRACERx100 cohort with high enough quality RNA available. There is RNAseq data from 164 regions (64 patients).
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples | 
|---|---|---|---|
| EGAD00001004591 | Illumina HiSeq 4000 | 164 | 
| Publications | Citations | 
|---|---|
| Neoantigen-directed immune escape in lung cancer evolution. Nature 567: 2019 479-485 | 458 | 
| Understanding the impact of immune-mediated selection on lung cancer evolution. Br J Cancer 124: 2021 1615-1617 | 3 | 
| Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 40: 2022 1624-1633 | 26 | 
| The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nat Cancer 4: 2023 608-628 | 16 | 
| Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin. J Clin Invest 133: 2023 e164397 | 6 | 
| Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion. iScience 27: 2024 110529 | 0 | 
